We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.76B Turnover 16.67%
1-Year Est. Return 342.13%
This Fund
S&P 500
This Quarter Est. Return
+47.31%
1 Year Est. Return
+342.13%
3 Year Est. Return
+2,581.87%
5 Year Est. Return
+47,632.22%
10 Year Est. Return
–
AUM
$3.76B
AUM Growth
-$10.4M
Cap. Flow
-$9.05M
Cap. Flow %
-0.24%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
3
Reduced
2
Closed
1
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$1.23B
2
ABVX icon
Abivax
ABVX
+$17.3M
3
BLTE icon
Belite Bio
BLTE
+$3.04M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$1.26B
2
ROIV icon
Roivant Sciences
ROIV
+$1.48M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$1.46M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RVMD icon
1
Revolution Medicines
RVMD
$39.2B
$2.05B 54.45%
10,629,822
+8,418,804
+381% +$1.23B
2026 Q1
1 quarter
INSM icon
2
Insmed
INSM
$21B
$674M 17.91%
6,431,163
-10,374,021
-62% -$1.26B
2024 Q2
8 quarters
BLTE icon
3
Belite Bio
BLTE
$5.83B
$457M 12.14%
3,077,219
+19,807
+0.6% +$3.04M
2025 Q4
2 quarters
ABVX icon
4
Abivax
ABVX
$7.64B
$348M 9.26%
3,621,583
+152,926
+4% +$17.3M
2025 Q3
3 quarters
ROIV icon
5
Roivant Sciences
ROIV
$25.1B
$234M 6.23%
6,747,300
-50,000
-0.7% -$1.48M
2026 Q1
1 quarter
DNTH icon
6
Dianthus Therapeutics
DNTH
$4.23B
– –
-17,357
Closed -$1.46M –

Similar funds

Close Asset Management
Close Asset Management London, United Kingdom $3.76B AUM 40.73% 1-Year Est. Return
Ameritas Investment Partners
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
American Securities
American Securities New York $3.75B AUM 23.12% 1-Year Est. Return
Miller Howard Investments
Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return
Hyperion Asset Management
Hyperion Asset Management Brisbane, Australia $3.77B AUM 16.13% 1-Year Est. Return
Gerber Kawasaki Wealth & Investment Management
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return
Bragg Financial Advisors
Bragg Financial Advisors Charlotte, North Carolina $3.74B AUM 39.87% 1-Year Est. Return
FAM
Foxhaven Asset Management Charlottesville, Virginia $3.73B AUM 2.63% 1-Year Est. Return

Darwin Global Management's Q2 2026 Portfolio in Review

As of Q2 2026, Darwin Global Management held 6 positions worth $3.76B, down 0.28% from $3.77B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management's Q2 2026 filing shows 3 increased, 2 reduced and 1 closed positions. The largest sale was Insmed, an estimated $1.26B.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Darwin Global Management added most to Revolution Medicines in Q2 2026, an estimated $1.23B increase.
  • Darwin Global Management's biggest Q2 2026 reduction was Insmed, cutting an estimated $1.26B.
  • Darwin Global Management fully exited Dianthus Therapeutics in Q2 2026, selling an estimated $1.46M.
  • Darwin Global Management's ten largest holdings make up 100% of its $3.76B portfolio in Q2 2026.
  • Darwin Global Management opened 0 new positions and closed 1 in Q2 2026.
  • Darwin Global Management's portfolio value fell 0.28% quarter-over-quarter to $3.76B.

Based on Darwin Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.